Header

UZH-Logo

Maintenance Infos

Publications for Agarwala, S S

Navigate back| Up a level
Export as
Group by:
Number of items: 7.

2019

Ascierto, Paolo A; Agarwala, Sanjiv S; Botti, Gerardo; Budillon, Alfredo; Davies, Michael A; Dummer, Reinhard; Ernstoff, Marc; Ferrone, Soldano; Formenti, Silvia; Gajewski, Thomas F; Garbe, Claus; Hamid, Omid; Lo, Roger S; Luke, Jason J; Michielin, Oliver; Palmieri, Giuseppe; Zitvogel, Laurence; Marincola, Francesco M; Masucci, Giuseppe; Caracò, Corrado; Thurin, Magdalena; Puzanov, Igor (2019). Perspectives in melanoma: meeting report from the Melanoma Bridge (November 29th-1 December 1st, 2018, Naples, Italy). Journal of Translational Medicine, 17(1):234.

van Herpen, Carla M L; Agarwala, Sanjiv S; Hauschild, Axel; Berking, Carola; Beck, J Thaddeus; Schadendorf, Dirk; Jansen, Rob; Queirolo, Paola; Ascierto, Paolo A; Blank, Christian U; Heinrich, Michael C; Pal, Rupam R; Derti, Adnan; Antona, Victor; Nauwelaerts, Heidi; Zubel, Angela; Dummer, Reinhard (2019). Biomarker results from a phase II study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS- or BRAF-mutated melanoma. OncoTarget, 10(19):1850-1859.

2018

Ascierto, Paolo A; Puzanov, Igor; Agarwala, Sanjiv S; Bifulco, Carlo; Botti, Gerardo; Caracò, Corrado; Ciliberto, Gennaro; Davies, Michael A; Dummer, Reinhard; Ferrone, Soldano; Gajewski, Thomas F; Garbe, Claus; Luke, Jason J; Marincola, Francesco M; Masucci, Giuseppe; Mehnert, Janice M; Mozzillo, Nicola; Palmieri, Giuseppe; Postow, Michael A; Schoenberger, Stephen P; Wang, Ena; Thurin, Magdalena (2018). Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy). Journal of Translational Medicine, 16(1):207.

2017

Ascierto, Paolo A; Agarwala, Sanjiv S; Ciliberto, Gennaro; Demaria, Sandra; Dummer, Reinhard; Duong, Connie P M; Ferrone, Soldano; Formenti, Silvia C; Garbe, Claus; Halaban, Ruth; Khleif, Samir; Luke, Jason J; Mir, Lluis M; Overwijk, Willem W; Postow, Michael; Puzanov, Igor; Sondel, Paul; Taube, Janis M; Thor Straten, Per; Stroncek, David F; Wargo, Jennifer A; Zarour, Hassane; Thurin, Magdalena (2017). Future perspectives in melanoma research "Melanoma Bridge", Napoli, November 30th-3rd December 2016. Journal of Translational Medicine, 15(1):236.

2015

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

2013

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, 14(3):249-256.

2011

Patel, P M; Suciu, S; Mortier, L; Kruit, W H; Robert, C; Schadendorf, D; Trefzer, U; Punt, C J A; Dummer, R; Davidson, N; Becker, Juergen; Conry, R; Thompson, J A; Hwu, W J; Engelen, K; Agarwala, S S; Keilholz, U; Eggermont, A M M; Spatz, A (2011). Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: Final results of a randomised phase III study (EORTC 18032). European Journal of Cancer, 47(10):1476-1483.

This list was generated on Mon Sep 16 00:19:48 2019 CEST.